Research and Markets (http://www.researchandmarkets.com/research/d3e55b/pediatric_board_re) has announced the addition of the "Pediatric Board Review" report to their offering. [More]

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has expanded its leading medical imaging capabilities with advanced nuclear imaging functionality for cardiology clinical trials. [More]

Waters Corporation (NYSE: WAT) today hosted Dr. Lawrence Zintek, National Organic Methods Development Expert, United States Environmental Protection Agency Region 5 Central Regional Laboratory in Chicago, and author of two new rapid screening methods for Alkylphenols and Bisphenol A (BPA) using Waters® ACQUITY UPLC®/Quattro Premier(TM) XE (UPLC/MS/MS) recently published in American Society for Testing and Materials (ASTM) International. Dr. Zintek was the keynote speaker at a Waters' breakfast seminar held in conjunction with the Water Quality Technology Conference sponsored by the American Water Works Association in Seattle. [More]

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]

Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer. [More]

Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510. [More]

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009. [More]

Life Science Analytics', Metabolic Endocrinology Hypocalcemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of endocrinology drugs by company and by stage as well as a summary of the latest news and developments in this area. [More]

Women's sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets. [More]

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-delivery transdermal patch (ZP-PTH) for the treatment of postmenopausal osteoporosis. [More]

In their American Society of Reproductive Medicine (ASRM) conference wrap-up, Medscape highlighted the article published by them on October 27, 2009, which summarized the results from the largest prospective, randomized clinical study to compare vaginal progesterone to intramuscular progesterone injections (IM progesterone) for luteal support in infertility treatment. [More]

Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone. [More]

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009. [More]

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2009. [More]

Merck & Co., Inc. today outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation announced yesterday. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value. [More]